Enlicitide
Overview
Enlicitide is an investigational peptide agonist designed to modulate metabolic pathways involved in energy balance and glucose homeostasis. Limited publicly available structural and mechanistic data suggest it may target incretin or related neuroendocrine pathways, though detailed receptor pharmacology has not been fully disclosed in the peer-reviewed literature. The compound is being explored for potential applications in obesity and metabolic disorders.
Key Research Findings
Preclinical studies have characterized pharmacokinetic profiles and receptor engagement, but detailed clinical trial results remain sparse in the published literature as of 2024. The development status and sponsoring organization have not widely publicized phase 2 or phase 3 outcomes, indicating the compound remains in early investigational stages.
Subcutaneous injection
Investigational
Interested in Enlicitide?
Find a verified provider experienced with Enlicitide protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Enlicitide ProviderRelated Peptides
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and acts on hypothalamic GLP-1 receptors to reduce appetite. Its fatty acid side chain enables albumin binding, extending its half-life to approximately 7 days.
Tirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activates both incretin pathways simultaneously, producing superior glycemic control and weight loss compared to selective GLP-1 RAs. The dual mechanism enhances insulin sensitivity and lipid metabolism beyond what either pathway achieves alone.
Retatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The glucagon receptor component adds thermogenic energy expenditure and hepatic lipid mobilization to the incretin-mediated appetite suppression and insulin sensitization. This triple mechanism addresses obesity through complementary metabolic pathways.
AOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine at the N-terminus. AOD-9604 retains the lipolytic activity of hGH without its growth-promoting or diabetogenic effects. It stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from the GH receptor, acting on beta-3 adrenergic receptors in adipose tissue.